Anne-Laure Barbotin1, Caroline Ballot1, Julien Sigala1, Nassima Ramdane1, Alain Duhamel1, François Marcelli1, Jean-Marc Rigot2, Didier Dewailly1, Pascal Pigny1, Valerie Mitchell3. 1. Institut de Biologie de la Reproduction-Spermiologie-CECOSCentre Hospitalier Régional Universitaire CHRU, F-59037 Lille, FranceUnité de BiostatistiquesCHRU, F-59037 Lille, FranceService d'AndrologieHôpital A. Calmette, CHRU, F-59037 Lille, FranceEA4308 <ce:italic>Gametogenese et qualite du gamete</ce:italic>F-59037 Lille, FranceService de Gynecologie Endocrinienne et de Medecine de la ReproductionCHRU, F-59037 Lille, FranceLaboratoire de Biochimie et HormonologieCentre de Biologie et Pathologie, CHRU, F-59037 Lille, France. 2. Institut de Biologie de la Reproduction-Spermiologie-CECOSCentre Hospitalier Régional Universitaire CHRU, F-59037 Lille, FranceUnité de BiostatistiquesCHRU, F-59037 Lille, FranceService d'AndrologieHôpital A. Calmette, CHRU, F-59037 Lille, FranceEA4308 <ce:italic>Gametogenese et qualite du gamete</ce:italic>F-59037 Lille, FranceService de Gynecologie Endocrinienne et de Medecine de la ReproductionCHRU, F-59037 Lille, FranceLaboratoire de Biochimie et HormonologieCentre de Biologie et Pathologie, CHRU, F-59037 Lille, France Institut de Biologie de la Reproduction-Spermiologie-CECOSCentre Hospitalier Régional Universitaire CHRU, F-59037 Lille, FranceUnité de BiostatistiquesCHRU, F-59037 Lille, FranceService d'AndrologieHôpital A. Calmette, CHRU, F-59037 Lille, FranceEA4308 <ce:italic>Gametogenese et qualite du gamete</ce:italic>F-59037 Lille, FranceService de Gynecologie Endocrinienne et de Medecine de la ReproductionCHRU, F-59037 Lille, FranceLaboratoire de Biochimie et HormonologieCentre de Biologie et Pathologie, CHRU, F-59037 Lille, France. 3. Institut de Biologie de la Reproduction-Spermiologie-CECOSCentre Hospitalier Régional Universitaire CHRU, F-59037 Lille, FranceUnité de BiostatistiquesCHRU, F-59037 Lille, FranceService d'AndrologieHôpital A. Calmette, CHRU, F-59037 Lille, FranceEA4308 <ce:italic>Gametogenese et qualite du gamete</ce:italic>F-59037 Lille, FranceService de Gynecologie Endocrinienne et de Medecine de la ReproductionCHRU, F-59037 Lille, FranceLaboratoire de Biochimie et HormonologieCentre de Biologie et Pathologie, CHRU, F-59037 Lille, France Institut de Biologie de la Reproduction-Spermiologie-CECOSCentre Hospitalier Régional Universitaire CHRU, F-59037 Lille, FranceUnité de BiostatistiquesCHRU, F-59037 Lille, FranceService d'AndrologieHôpital A. Calmette, CHRU, F-59037 Lille, FranceEA4308 <ce:italic>Gametogenese et qualite du gamete</ce:italic>F-59037 Lille, FranceService de Gynecologie Endocrinienne et de Medecine de la ReproductionCHRU, F-59037 Lille, FranceLaboratoire de Biochimie et HormonologieCentre de Biologie et Pathologie, CHRU, F-59037 Lille, France valerie.mitchell@chru-lille.fr.
Abstract
OBJECTIVE: Although an inhibin B assay may be useful in the assessment of testicular function in a number of genital conditions, reliable reference ranges are still lacking. The present study sought to establish the reference range for serum inhibin B by applying the updated Gen II assay. DESIGN: This prospective study included 818 men referred for semen analysis: 377 were normozoospermic (reference group) and 441 presented at least one abnormal semen parameter (case group). METHODS: Semen parameters were interpreted according to the 2010 World Health Organization manual and David's modified classification for normal morphology. The inhibin B concentration was determined with the current ELISA. RESULTS: In the reference group, the 2.5th percentile for inhibin B was 92 pg/ml and the 97.5th percentile for FSH was 7.8 IU/l. In the overall population, an inhibin B level <92 pg/ml was associated with increased odds ratio (OR; 95% CI) for oligozoospermia (16.93 (9.82-29.18), P<0.0001), asthenozoospermia (4.87 (2.88-8.10), P<0.0001), and teratozoospermia (2.20 (1.31-3.68), P=0.0026). The combination of a FSH >7.8 IU/l and an inhibin B <92 pg/ml was associated with greater OR for oligozoospermia (98.74 (23.99-406.35), P<0.0001) than for each hormone considered separately. CONCLUSIONS: A new reference range for serum inhibin B was established by the use of updated immunoassay. The correlations between hormone levels and semen parameters highlighted the importance of establishing these values with respect to the spermogram. When combined with FSH assay, the inhibin B range may be of value in the evaluation of spermatogenesis in a number of male genital conditions.
OBJECTIVE: Although an inhibin B assay may be useful in the assessment of testicular function in a number of genital conditions, reliable reference ranges are still lacking. The present study sought to establish the reference range for serum inhibin B by applying the updated Gen II assay. DESIGN: This prospective study included 818 men referred for semen analysis: 377 were normozoospermic (reference group) and 441 presented at least one abnormal semen parameter (case group). METHODS: Semen parameters were interpreted according to the 2010 World Health Organization manual and David's modified classification for normal morphology. The inhibin B concentration was determined with the current ELISA. RESULTS: In the reference group, the 2.5th percentile for inhibin B was 92 pg/ml and the 97.5th percentile for FSH was 7.8 IU/l. In the overall population, an inhibin B level <92 pg/ml was associated with increased odds ratio (OR; 95% CI) for oligozoospermia (16.93 (9.82-29.18), P<0.0001), asthenozoospermia (4.87 (2.88-8.10), P<0.0001), and teratozoospermia (2.20 (1.31-3.68), P=0.0026). The combination of a FSH >7.8 IU/l and an inhibin B <92 pg/ml was associated with greater OR for oligozoospermia (98.74 (23.99-406.35), P<0.0001) than for each hormone considered separately. CONCLUSIONS: A new reference range for serum inhibin B was established by the use of updated immunoassay. The correlations between hormone levels and semen parameters highlighted the importance of establishing these values with respect to the spermogram. When combined with FSH assay, the inhibin B range may be of value in the evaluation of spermatogenesis in a number of male genital conditions.
Authors: A Ferlin; A E Calogero; C Krausz; F Lombardo; D Paoli; R Rago; C Scarica; M Simoni; C Foresta; V Rochira; E Sbardella; S Francavilla; G Corona Journal: J Endocrinol Invest Date: 2022-01-24 Impact factor: 4.256
Authors: Jon Jarløv Rasmussen; Christian Selmer; Peter Busch Østergren; Karen Boje Pedersen; Morten Schou; Finn Gustafsson; Jens Faber; Anders Juul; Caroline Kistorp Journal: PLoS One Date: 2016-08-17 Impact factor: 3.240
Authors: Alessandra Petrozzi; Francesco Pallotti; Marianna Pelloni; Antonella Anzuini; Antonio Francesco Radicioni; Andrea Lenzi; Donatella Paoli; Francesco Lombardo Journal: Asian J Androl Date: 2019 Jul-Aug Impact factor: 3.285